The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective

[1] Lombel RM(2013)Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO PediatrNephrol 28 415-426

[2] Gipson DS(2015)The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Sci Rep 5 8219-1315

[3] Hodson EM(2011)Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 1308-2266

[4] Zhao Z(2015)Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial J Am SocNephrol 26 2259-1281

[5] Liao G(2014)Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 1273-1270

[6] Li Y(2013)Efficacy and safety of rituximab in children with refractory nephrotic syndrome; a multicenter clinical trial Pediatr Nephrol 28 1361-undefined

[7] Zhou S(2014)Ofatumumab for rituximab-resistant nephrotic syndrome N Engl J Med 370 1268-undefined

[8] Zou H(2015)Low-dose ofatumumab for rituximab-resistant nephrotic syndrome BMJ Case Rep 16 2015-undefined

[9] Ravani P(undefined)undefined undefined undefined undefined-undefined

[10] Magnasco A(undefined)undefined undefined undefined undefined-undefined

[1] Lombel RM(2013)Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO PediatrNephrol 28 415-426

[2] Gipson DS(2015)The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Sci Rep 5 8219-1315

[3] Hodson EM(2011)Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 1308-2266

[4] Zhao Z(2015)Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial J Am SocNephrol 26 2259-1281

[5] Liao G(2014)Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 1273-1270

[6] Li Y(2013)Efficacy and safety of rituximab in children with refractory nephrotic syndrome; a multicenter clinical trial Pediatr Nephrol 28 1361-undefined

[7] Zhou S(2014)Ofatumumab for rituximab-resistant nephrotic syndrome N Engl J Med 370 1268-undefined

[8] Zou H(2015)Low-dose ofatumumab for rituximab-resistant nephrotic syndrome BMJ Case Rep 16 2015-undefined

[9] Ravani P(undefined)undefined undefined undefined undefined-undefined

[10] Magnasco A(undefined)undefined undefined undefined undefined-undefined